SBIR/STTR Research Award
Monobody therapy for gynecologic cancers
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Panorama Research Incorporated
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LYVHC3ARFRJ7
- Solicitation number
- PA13-088
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Monobody Therapy for Gynecologic Cancers Endometrial cancer is the most common gynecologic cancer in the western world. Systemic treatments for advanced disease have traditionally included hormonal therapy and chemotherapy. Responses to treatment are short-lived, and advanced-stage disease remains incurable. Ovarian cancer is the eighth most common cancer and causes more deaths than any other gynecologic cancer. Increasing evidence implicates prolactin (PRL) as a key factor in endometrial and ovarian cancer. Elevated levels of circulating PRL in gynecologic cancer suggest a role for PR L in endometrial and ovarian carcinogenesis. Recent studies have found significantly elevated expression of PRL in women with a strong family history of ovarian cancer. In addition, PRL receptor (PRLR) expression is upregulated in endometrial tumors, as well as in premalignant endometrial hyperplasia. Recent histochemical data found PRLR expression in gt80% of ovarian tumors, but in non
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Therapy for Sarcopenia
- Novel therapy to prevent alveolar bone loss in severe periodontitis
- Novel therapy for arthrofibrosis
- Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
- Monoclonal antibody for autoimmune disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
149 SBIR/STTR records share this UEI (1990–2025). Reported award amounts total $35,373,004. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Agriculture, National Science Foundation